ABVX$88.714.48%3.80
Pre-market: 90.50+1.79 +2.02%
Abivax Adr (ABVX)
Date: 2026-11-03 16:00O: 85.37H: 90.12L: 85.26C: 88.71Vol: 585.6k
Abivax Adr stock is traded at $88.71, with a volume of 585,619. It is up +4.48% in the last 24 hours and down -4.49% over the past month. Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Previous Close:
$84.91
Open:
$85.37
24h Volume:
585,619
Relative Volume:
0.87
Market Cap:
$7.77B
Revenue:
-
Net Income/Loss:
-$386.19M
P/E Ratio:
-
EPS:
-$5.25
Net Cash Flow:
-$206.27M
1W Performance:
-1.26%
1M Performance:
-4.49%
6M Performance:
-24.26%
1Y Performance:
-10.07%
1-Day Range:
$0.00$0.00
1-Week Range:
$83.55$92.09
52-Week Range:
$69.81$148.83
Abivax Adr Stock (ABVX) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS
Abivax Adr Stock (ABVX) Upgrades & Downgrades
Abivax Adr Stock (ABVX) Financials Data
There is no financial data for Abivax Adr (ABVX). Check out other stocks for more information.
Abivax Adr Stock (ABVX) Insider Trading
- Sofinnova Crossover I SLPJan 08 '26Affiliate
- Transaction
- Proposed Sale
- Cost
- $133.70
- #Shares
- 1,000,000
- Value ($)
- 133,700,000
- #Shares Total
- 0
- Sofinnova Crossover I SLPOct 28 '25Affiliate
- Transaction
- Proposed Sale
- Cost
- $92.75
- #Shares
- 1,200,000
- Value ($)
- 111,300,000
- #Shares Total
- 0
